This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Is iShares Core High Dividend ETF (HDV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for HDV
Should iShares Core High Dividend ETF (HDV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for HDV
5 Winning ETF Strategies for the Second Half
by Sweta Killa
We have highlighted some winning strategies that could prove to be extremely beneficial for investors in the second half of 2021.
A Guide to 10 Most-Popular Dividend ETFs
by Sweta Killa
The dividend-focused products offer safety through payouts, and stability in the form of mature companies that are less volatile amid large swings in stock prices.
5 Popular US Dividend ETFs That Yield More Than Treasuries
by Sweta Killa
We have highlighted five ETFs that yield more than 5% and could be compelling plays this year.
Guide to High Dividend Paying ETFs
by Sanghamitra Saha
All dividend stocks o not serve the same purpose. While stocks with dividend growth point to quality investing, the high-yield ones are known for offering hefty current income.
ETFs to Play as Beginning of Biden Era May Prompt Market Rally
by Sanghamitra Saha
In year one of a Democratic presidency, the S&P 500 has gained on average by 19.4% dating back to 1932, per data crunched by BMO Capital Markets, as quoted on Yahoo Finance.
ETFs to Shine as Pfizer's COVID-19 Vaccine Gets a Nod in Europe
by Sweta Jaiswal, FRM
Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging progress in coronavirus vaccine development.
Pfizer's Coronavirus Vaccine Gets a Nod in UK: ETFs to Shine
by Sweta Jaiswal, FRM
Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging progress in coronavirus vaccine development.
What Lies Ahead for Pfizer ETFs After Another Round of Upbeat Vaccine Data
by Sweta Jaiswal, FRM
Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging progress in the coronavirus vaccine development.